Safety and tolerability of subcutaneous immunoglobulin 20% in primary immunodeficiency diseases from two continents. [electronic resource]
Producer: 20200525Description: 1057-1065 p. digitalISSN:- 1750-7448
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Child
- Child, Preschool
- Drug-Related Side Effects and Adverse Reactions -- epidemiology
- Europe
- Female
- Humans
- Immunoglobulin G -- therapeutic use
- Injections, Subcutaneous
- Male
- Middle Aged
- North America
- Primary Immunodeficiency Diseases -- drug therapy
- Prospective Studies
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.